Indivior to pay $600 million to resolve U.S. opioid treatment marketing claims

(Reuters) – Indivior Plc on Friday said it had agreed to pay $600 million and have a subsidiary plead guilty to a criminal charge to resolve U.S. allegations that it engaged in an illegal scheme to boost prescriptions of its opioid addiction treatment Suboxone.

The company said it had reached the agreement with the U.S. Justice Department, the Federal Trade Commission and U.S. state attorneys general and will make the payments over a period of seven years.

(Reporting by Nate Raymond in Boston; editing by Jonathan Oatis)